The correlation between small papillary thyroid cancers and gamma radionuclides Cs-137, Th-232, U-238 and K-40 using spatially-explicit, register-based methods - Bayadsi, Haytham; Van Den Brink, Paul; Erlandsson, M arten; Gudbjornsdottir, Soffia; Sebraoui, Samy; Koorem, Sofi; Nordin, Pär; Hennings, Joakim; Englund, Oskar (medRxiv, 2023)
A steep increase of small papillary thyroid cancers (sPTCs) has been observed globally. A major risk factor for developing PTC is ionizing radiation. The aim of this study is to investigate whether geological differences in the prevalence of sPTCs in Sweden are correlated to the deposit of Caecium-137, Thorium-232 (Th-232), Uranium-238 (U-238) or Potassium-40 (K-40) using different Geographical Information System (GIS) methods. Datasets of 812 sPTC patients were combined with the datasets of the total population in Sweden and were layered with the gamma radionuclide deposits. The prevalence of metastatic sPTC was associated with significantly higher levels of Gamma radiation from Th-232, U-238 and K-40. The observed results clearly indicate that sPTC has causative factors that are neither evenly distributed among the population, nor geographically, calling for further studies with bigger cohorts where environmental factors are believed to play a major role in the pathogenesis of the disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Unit of Research Education and Development, Jamtland-Harjedalen County, Sweden (Grant number: JLL-940567) and Jamtland County Cancer and Care Fund, Sweden (Grant number: 748). Open access funding provided by Umea University, Sweden.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Swedish Ethical Review Authority, permit number 2019-04983, and was carried out in accordance with the EUs General Data Protection Regulation (GDPR) rules.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsTCThyroid cancerPTCPapillary thyroid cancersPTCSmall papillary thyroid cancerPTCMPapillary thyroid microcarcinomaGISGeographic Information SystemQGISQuantum Geographic Information SystemGRASSGeographic Resources Analysis Support SystemCs-137Caesium-137Th-232Thorium-232U-238Uranium-238K-40Potassium-40SQRTPAScandinavian Quality Register for Thyroid, Parathyroid and Adrenal SurgeryAPIApplication Program Interface